Europa Biosite acquires MEDISTA, expanding into the Czech Republic & strengthening diagnostics capabilities
Advertisement
Europa Biosite announced the acquisition of MEDISTA spol. s r.o., a specialist distributor of diagnostics and laboratory technology in the Czech Republic. The acquisition is subject to customary regulatory approvals.
The addition of MEDISTA marks another milestone in Europa Biosite’s growth, expanding the Group into the Czech Republic for the first time and significantly strengthening its capabilities in diagnostics. MEDISTA brings valuable diagnostics knowledge and experience to Europa Biosite, complementing the Group’s established life science distribution businesses across Europe and North America.
MEDISTA will continue to operate under the MEDISTA name and maintain the local expertise, customer focus and relationships that have been central to the business. MEDISTA’s directors, Jan Kadlec and Alexandra Kadlecová, will continue in their respective roles. Jan Kadlec, CEO of MEDISTA, will also join the Europa Biosite Group Leadership Team, bringing his knowledge and experience of the diagnostics market to the wider Group.
Claudia Berrón, CEO of Europa Biosite, commented: “I am pleased to welcome the MEDISTA team to Europa Biosite. MEDISTA is a strong addition to Europa Biosite, bringing valuable diagnostics expertise, strong customer and supplier relationships and deep knowledge of the Czech market. I look forward to working together to support customers, suppliers, and accelerate our continued growth.”
Jan Kadlec, CEO of MEDISTA, commented: “Joining Europa Biosite represents an exciting new chapter for MEDISTA. Becoming part of a wider international Group gives us the opportunity to build on our existing strengths while benefiting from the expertise, resources and network across Europa Biosite.
Our commitment to our customers, suppliers and partners remains unchanged, and I look forward to continuing to lead MEDISTA while contributing to the future development of Europa Biosite”.
The acquisition of MEDISTA is the latest step in Europa Biosite’s continued expansion. Our ambition is to bring together leading European life science and diagnostics businesses with strong local market knowledge, technical expertise and established customer and supplier relationships, creating a European platform that gives customers greater access to specialist products, knowledge and support, while giving suppliers a high-performing route to market.
Europa Biosite will continue to pursue this ambition through both organic growth and further strategic acquisitions that expand our geographic presence and strengthen our specialist capabilities.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.